Published in Cardiovasc Diabetol on September 25, 2015
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal function. Sci Rep (2016) 0.75
Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults. Metabolism (2017) 0.75
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem (2004) 1.95
Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol (2005) 1.70
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care (2005) 1.34
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia (1997) 1.24
Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol (1995) 1.24
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) (2010) 1.24
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol (2007) 1.23
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol (2013) 1.21
Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis (2011) 1.17
Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun (2008) 1.17
Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem (2005) 1.11
Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis (2008) 1.11
Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care (2010) 1.09
Vascular biomarkers and surrogates in cardiovascular disease. Circulation (2006) 1.09
Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism (2003) 1.09
The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (2014) 1.02
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res (2008) 1.02
Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol (2014) 0.94
Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes (2007) 0.92
The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care (1998) 0.92
Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol (2013) 0.91
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc (2006) 0.90
Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis (2009) 0.88
Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS One (2012) 0.87
The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging. Fertil Steril (2009) 0.86
Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med (2013) 0.86
Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis (2014) 0.83
Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: a possible association with ECM metabolism. Mech Ageing Dev (2012) 0.81
The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol (2011) 0.81
Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. J Biochem (2009) 0.80
Differential effect of plasma or erythrocyte AGE-ligands of RAGE on expression of transcripts for receptor isoforms. Diabetes Metab (2009) 0.79
Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG (2012) 0.77